Don Dion's  Instablog

Don Dion
  • on IPO Analysis
Send Message
Don Dion (, @DRDInvestments) is the owner and Chief Investment Officer of DRD Investments, LLC, based in Naples, FL. and Williamstown, MA., a family office focused on managing a long/short hedge fund, real estate assets, venture capital, and various other financial assets for... More
My company:
Drd investments, llc
My blog:
Don Dion's IPO Analysis
My book:
The Ultimate Guide to Trading ETFs
  • With Strong Partners, Ardelyx IPO Is A Buy For Aggressive Investors 1 comment
    Jun 19, 2014 8:54 AM | about stocks: AZN, ARDX

    Ardelyx, Inc (NASDAQ:ARDX), a clinical-stage biopharmaceutical firm, seeking to develop small-molecule therapeutics for cardio-renal, gastrointestinal and metabolic diseases, plans to raise $50.4 million in its upcoming IPO.

    The Fremont, California-based firm will offer 3.6 million shares at an expected price range of $13-$15 per share. If the IPO can reach the midpoint of that range at $14 per share, ARDX will command a market value of $252 million.

    ARDX filed on May 19, 2014

    Lead Underwriters: Citigroup Global Markets Inc; Leerink Partners LLC

    Underwriters: JMP Securities LLC; Wedbush Securities Inc

    Summary: Gastro-intestinal and Metabolic Disease Treatment

    ARDX is a clinical-stage biopharmaceutical firm, engaged in the discovery, development and commercialization of non-systemic, small-molecule therapeutics to operate in the gastrointestinal tract and treat cardio-renal, gastrointestinal and metabolic diseases.

    The firm has made a habit of forming partnerships with established pharmaceutical firms to develop and commercialize its treatments.

    ARDX's tenapanor is currently in Phase 2 trials for patients with late-stage chronic kidney disease (CKD), end-stage renal disease (ESRD), and constipation-predominant irritable bowel syndrome (IBS-C) in collaboration with AstraZeneca (NYSE:AZN); AstraZeneca is funding all research and development of tenapanor, while ARDX could potentially receive hundreds of millions in milestone payments as well as tiered royalties. The firm has also licensed the development of small moleculle NaP2b inhibitors for the treatment of hyperphosphatemia-elevated phosphorus-in ESRD to Sanofi S.A.

    ARDX's drug discovery program is supplemented by a cell-culture system that the company has created to simulate gut tissues called the Ardelyx Primary Enterocyte and Colonocyte Culture System (APECCS). The firm has identified more than 3,800 proteins on the gut's inner surface, which it may be able to target with drugs in the future.

    (click to enlarge)



    ARDX offers the following figures in its S-1 balance sheet for the three months ended March 31, 2014:

    Revenue: $8,550,000.00

    Net Loss: ($3,071,000.00)

    Total Assets: $40,548,000.00

    Total Liabilities: $50,851,000.00

    Stockholders' Equity: ($66,458,000.00)

    As none of ARDX's products have yet been commercialized, its losses are unsurprising. The firm has generated some revenue through its partnerships with Sanofi and AstraZeneca, but will not be able to create sustainable revenue streams until its products have been further developed and commercialized.

    Big Competitors

    ARDX's products, if approved, would compete with other products intended to treat the same conditions, including many that are in development or marketed by established firms with far greater financial and marketing resources than ARDX has available.

    These competitors could include the likes of Genzyme Corp., Impax Laboratories, Inc (NASDAQ:IPXL), Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), Opko Health Inc (NYSEMKT:OPK), Sorbent Therapeutics, Concert Pharmaceuticals, and Ironwood Pharmaceuticals (NASDAQ:IRWD).

    Management Highlights

    President and CEO Michael Raab has served in his current roles since 2009.

    Mr. Raab was previously a partner at New Enterprise Associates, where he specialized in healthcare investments in the biotechnology and pharmaceutical sectors. He also served as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, and worked in various business development and sales and marketing positions at Repligen Corporation and Bristol-Myers Squibb Company.

    Mr. Raab holds a B.A. from DePauw University.

    Conclusion For Investors

    We are positive on this IPO.

    ARDX's products all will face significant competition from potent competitors in the event that they are able to gain regulatory approval, and there is no guarantee that they will be able to achieve even that.

    However, the firm has appreciably improved its odds by partnering with established firms like Sanofi and AstraZeneca and by pursuing multiple product candidates simultaneously.

    ARDX also benefits from an executive team well-versed in the business world and specifically in life sciences.

    We suggest investors considering buying into this IPO.

    We invite readers wishing to join the discussion on IPOs to click the +FOLLOW button above the title of this article and follow @DRDInvestments on twitter.

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.

    Stocks: AZN, ARDX
Back To Don Dion's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • mewa singh
    , contributor
    Comments (2) | Send Message
    Join us to beat generic and patent cliff
    A new treatment for GI


    Go Green Nanotechnology
    Please find attached information regarding the discovery in the field of nanomedicine. We would like to collaborate with you for resolving the solubility issues of your challenging molecules in the field of GI treatment. The nanotechnology we have discovered is totally new and 100% green process. We know the challenge to use nanotechnology in pharma industries are manufacturing cost and process control that has been taken care in our nanotechnology. It is the simplest to use and is one step process.


    Please contact us for more information.


    Dr Mewa Singh
    Meda Biotech llc.
    21 Aug 2014, 12:16 PM Reply Like
Full index of posts »
Latest Followers


  • $CXRX Expect CXRX to trade in sympathy with VRX today
    Aug 11, 2016
  • $DLTH Quiet Period Expiration is Today. Look for stock to power up.
    Dec 15, 2015
  • $HELE Expect upward move after the close today due to expected revenue and earnings beat
    Jul 9, 2015
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.